Please login to the form below

Not currently logged in


This page shows the latest Intellia news and features for those working in and with pharma, biotech and healthcare.

Sangamo’s first gene-editing trial doesn’t convince investors

Sangamo’s first gene-editing trial doesn’t convince investors

But companies developing other gene-editing technologies, such as CRISPR Therapeutics, Intellia Therapeutics and Editas Medicine, also saw their shares close down which might suggest an element of panic in the

Latest news

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    Earlier this month another CRISPR-Cas9 company, Intellia Therapeutics, raised $108m in an IPO to progress its early-stage programmes.

  • Deal Watch April 2016 Deal Watch April 2016

    265 . Intellia (US). Regeneron (US). Co-development &co-commercialisation. Discovery stage CRISPR/Cas platform for treatments of liver disease.

  • Deal Watch October 2015 Deal Watch October 2015

    companies. Other biotechs exploiting the CRISPR/Cas-9 technology for the development of therapeutics include Editas Medicine, Intellia Therapeutics and Caribou Biosciences; both Novartis and AstraZeneca have already developed collaborations in

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch